|
시장보고서
상품코드
2055242
내분비계 약물 시장 : 치료 영역별, 투여 경로별, 연령층별, 유통 채널별, 최종사용자별, 지역별Endocrinology Drug Market, By Therapy Area, By Route of Administration, By Age Group, By Distribution Channel, By End User, By Geography |
||||||
내분비계 약물 시장은 2026년 774억 4,000만 달러로 추정되며, 2033년까지 1,053억 9,000만 달러에 이를 것으로 예상되고 있습니다. 또한 2026-2033년 CAGR 4.5%를 기록할 전망입니다.
| 보고서 범위 | 보고서 상세 | ||
|---|---|---|---|
| 기준 연도 : | 2025년 | 2026년 시장 규모 : | 774억 4,000만 달러 |
| 과거 데이터 기간 : | 2020-2024년 | 예측 기간 : | 2026-2033년 |
| 예측 기간(2026-2033년) CAGR : | 4.50% | 2033년 시장 규모 예측 : | 1,053억 9,000만 달러 |
세계 내분비계 약물 시장은 전 세계 수백만 명에게 영향을 미치는 호르몬 장애 및 대사성 질환을 치료하는 매우 중요한 치료 분야입니다. 내분비학은 호르몬을 분비하는 샘과 그와 관련된 질환(당뇨병, 갑상선 기능 장애, 성장 호르몬 결핍증, 골다공증, 비만, 생식 호르몬 불균형 등)에 대한 연구를 포괄합니다. 이 분야의 제약 업계는 생명공학의 발전, 맞춤형 의료 접근법, 그리고 혁신적인 약물 전달 시스템에 힘입어 눈부신 발전을 이루어 왔습니다.
현대 내분비학 치료제는 인슐린 아날로그, GLP-1 수용체 작용제, SGLT-2 억제제, 갑상선 호르몬 대체 요법, 비스포스포네이트, 호르몬 대체 요법 등 다양한 약물 군에 이릅니다. 이 시장의 복잡성은 소아의 성장 장애부터 노인의 대사성 질환에 이르기까지, 개별적인 치료 요법이 필요한 다양한 환자층에서 기인합니다. 연속 혈당 모니터링, 스마트 인슐린 전달 시스템, 그리고 바이오마커 기반 진단 기술 분야의 기술적 돌파구는 치료 패러다임에 혁명을 일으켰으며, 정밀 의학 접근법을 가능하게 했습니다. 또한, 생활습관과 관련된 내분비 질환, 특히 당뇨병과 비만의 유병률 증가에 따라, 효능 향상과 부작용 감소를 동시에 달성한 차세대 치료제 개발을 위한 연구 투자와 규제 당국의 관심이 높아지고 있습니다.
시장 역학
세계 내분비계 약물 시장은 성장 궤도를 형성하는 여러 상호 연관된 요인들에 힘입어 견조한 성장세를 보이고 있습니다. 주요 시장 성장 요인으로는 전 세계 당뇨병 유병률의 급증이 꼽힙니다. 5억 명이 넘는 환자가 존재하며, 이는 혁신적인 혈당 관리 솔루션, 인슐린 요법 및 병용 치료에 대한 막대한 수요를 창출하고 있습니다. 고령화 또한 시장 확대에 크게 기여하고 있는데, 이는 고령자들이 갑상선 질환, 골다공증, 호르몬 불균형에 걸리기 쉬우며 장기적인 약물 치료가 필요하기 때문입니다. 서방형 메커니즘, 바이오시밀러 개발, 새로운 전달 시스템 등 제제 기술의 발전은 환자의 복약 순응도와 치료 성과를 향상시키는 동시에 시장의 혁신을 주도하고 있습니다.
그러나 시장 성장에는 특히 복잡한 생물학적 제제나 병용 요법의 경우, 제품 출시를 지연시키고 개발 비용을 증가시키는 엄격한 규제 승인 절차를 비롯해 상당한 제약이 따릅니다. 내분비학 분야의 블록버스터 의약품 특허 만료는 선발 기업에게 가격 압박과 시장 점유율 하락을 초래하는 한편, 전 세계적인 의료비 억제 정책은 보험 급여 정책과 접근성에 영향을 미치고 있습니다.
또한, 생물학적 제제와 관련된 제조 과정의 복잡성, 공급망의 취약성, 품질 관리 요건 등이 운영상의 과제로 대두되고 있습니다. 그럼에도 불구하고, 당뇨병 및 대사성 질환이 급속히 증가하고 있는 반면 치료 보급률은 여전히 낮은 개발도상국의 미개척 시장을 통해 큰 기회가 창출되고 있습니다. 유전자 검사 및 바이오마커 식별을 활용한 맞춤형 의료 접근법은 표적 치료제에 있어 유망한 전망을 제시하고 있습니다. 원격의료 플랫폼 및 AI를 활용한 치료 최적화를 포함한 디지털 헬스케어의 통합은 새로운 수익원을 창출하고 환자 참여도를 높이고 있으며, 기존의 과제에도 불구하고 내분비계 의약품 시장은 지속적인 성장 궤도에 올라 있습니다.
본 조사의 주요 특징
- 본 조사에서는 각 부문의 잠재적 수익 기회를 파악하고, 이 시장에서 매력적인 투자 제안 매트릭스에 대해 설명하고 있습니다.
- 또한, 본 조사에서는 시장 성장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 그리고 주요 기업들이 채택하는 경쟁 전략에 관한 중요한 인사이트를 제공합니다.
- 본 조사에서는 다음의 주요 항목(기업 개요, 제품 포트폴리오, 주요 성과, 재무 실적, 전략)을 바탕으로 전 세계 내분비계 약물 시장의 주요 기업 프로파일을 작성하였습니다.
- 본 보고서의 인사이트를 활용함으로써, 기업의 마케팅 담당자와 경영진은 향후 제품 출시, 제품 업그레이드, 시장 확대 및 마케팅 전략에 관해 정보에 기반한 의사결정을 내릴 수 있게 됩니다.
- 본 세계의 내분비계 약물 시장 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진출기업, 금융 애널리스트 등 이 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 세계 내분비계 약물 시장 분석에 활용되는 다양한 전략 매트릭스를 통해 의사결정을 보다 수월하게 내릴 수 있을 것입니다.
목차
제1장 조사 목적과 전제조건
제2장 시장 전망
제3장 시장 역학, 규제 및 동향 분석
제4장 세계의 내분비계 약물 시장 : 치료 영역별, 2021년-2033년
제5장 세계의 내분비계 약물 시장 : 투여 경로별, 2021년-2033년
제6장 세계의 내분비계 약물 시장 : 연령층별, 2021년-2033년
제7장 세계의 내분비계 약물 시장 : 유통 채널별, 2021년-2033년
제8장 세계의 내분비계 약물 시장 : 최종사용자별, 2021년-2033년
제9장 세계의 내분비계 약물 시장 : 지역별, 2021년-2033년
제10장 경쟁 구도
제11장 애널리스트의 제안
제12장 참고 문헌 및 조사 방법
LSH 26.06.23Endocrinology Drug Market is estimated to be valued at USD 77.44 Bn in 2026 and is expected to reach USD 105.39 Bn by 2033, growing at a compound annual growth rate (CAGR) of 4.5% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 77.44 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 4.50% | 2033 Value Projection: | USD 105.39 Bn |
The global endocrinology drug market represents a critical therapeutic segment addressing hormonal disorders and metabolic diseases that affect millions worldwide. Endocrinology encompasses the study of hormone-producing glands and their associated disorders, including diabetes mellitus, thyroid dysfunction, growth hormone deficiencies, osteoporosis, obesity, and reproductive hormone imbalances. The pharmaceutical landscape within this domain has witnessed remarkable evolution, driven by advancing biotechnology, personalized medicine approaches, and innovative drug delivery systems.
Modern endocrinology therapeutics span across various drug classes including insulin analogues, GLP-1 receptor agonists, SGLT-2 inhibitors, thyroid hormone replacements, bisphosphonates, and hormone replacement therapies. The market's complexity stems from diverse patient populations requiring tailored treatment regimens, ranging from pediatric growth disorders to geriatric metabolic conditions. Technological breakthroughs in continuous glucose monitoring, smart insulin delivery systems, and biomarker-driven diagnostics have revolutionized treatment paradigms, enabling precision medicine approaches. Additionally, the growing prevalence of lifestyle-related endocrine disorders, particularly diabetes and obesity, has intensified research investments and regulatory focus on developing next-generation therapeutics with improved efficacy profiles and reduced adverse effects.
Market Dynamics
The global endocrinology drug market experiences robust growth driven by multiple interconnected factors that shape its trajectory. Primary market drivers include the escalating prevalence of diabetes worldwide, with over 500 million affected individuals creating substantial demand for innovative glucose management solutions, insulin therapies, and combination treatments. Aging demographics contribute significantly to market expansion as elderly populations exhibit higher susceptibility to thyroid disorders, osteoporosis, and hormonal imbalances requiring long-term pharmaceutical interventions. Technological advancements in drug formulation, including extended-release mechanisms, biosimilar development, and novel delivery systems, drive market innovation while improving patient compliance and therapeutic outcomes.
However, the market growth faces considerable restraints including stringent regulatory approval processes that delay product launches and increase development costs, particularly for complex biologics and combination therapies. Patent expirations of blockbuster endocrinology drugs create pricing pressures and market share erosion for originator companies, while healthcare cost containment measures globally impact reimbursement policies and accessibility.
Additionally, manufacturing complexities associated with biologic drugs, supply chain vulnerabilities, and quality control requirements pose operational challenges. Nevertheless, significant opportunities emerge through untapped markets in developing economies where diabetes and metabolic disorders are rapidly increasing but treatment penetration remains low. Personalized medicine approaches leveraging genetic testing and biomarker identification present lucrative prospects for targeted therapeutics. Digital health integration, including telemedicine platforms and AI-driven treatment optimization, creates new revenue streams and enhances patient engagement, positioning the endocrinology drug market for sustained growth despite existing challenges.
Key features of the study
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global endocrinology drug market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Novo Nordisk A/S, Eli Lilly and Company, Sanofi, Pfizer Inc, Merck & Co Inc, Novartis AG, AstraZeneca plc, AbbVie Inc, Takeda Pharmaceutical Company Limited, Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd, Ipsen Pharma, Teva Pharmaceutical Industries Ltd, Amgen Inc, and Bayer AG
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global endocrinology drug market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global endocrinology drug market
Market Segmentation
- Therapy Area Insights (Revenue, USD Bn, 2021 - 2033)
- Diabetes Management Drugs
- Insulin (short-acting, long-acting, and premixed)
- Oral Antidiabetics (biguanides, sulfonylureas, thiazolidinediones, etc.)
- GLP-1 Receptor Agonists
- Other Combination Therapies
- Thyroid Disorder Drugs
- Hypothyroidism Treatments (levothyroxine and liothyronine)
- Hyperthyroidism Treatments (antithyroid drugs and radioiodine therapy adjuncts)
- Growth Hormone Related Drugs
- Growth Hormone Deficiency Treatments (recombinant growth hormones, etc.)
- Acromegaly Treatments (somatostatin analogs, GH receptor antagonists, etc.)
- Adrenal Disorder Drugs
- Cushing's Syndrome Treatments (steroidogenesis inhibitors, pituitary-targeted drugs)
- Addison's Disease Treatments (glucocorticoids and mineralocorticoids)
- Congenital Adrenal Hyperplasia Drugs
- Reproductive Endocrinology Drugs
- Men's Health (testosterone therapies and anti-androgens)
- Women's Health (estrogen therapies, progesterone therapies, etc.)
- Fertility Drugs (gonadotropins, ovulation stimulants, etc.)
- Calcium and Bone Metabolism Drugs
- Osteoporosis Treatments (bisphosphonates, SERMs, calcitonin, etc.)
- Hyperparathyroidism Treatments (calcimimetics, vitamin D analogs, etc.)
- Route of Administration Insights (Revenue, USD Bn, 2021 - 2033)
- Oral
- Parenteral
- Transdermal (patches and gels)
- Nasal
- Others (e.g., sublingual, rectal)
- Age Group Insights (Revenue, USD Bn, 2021 - 2033)
- Pediatric
- Adult
- Geriatric
- Distribution Channel Insights (Revenue, USD Bn, 2021 - 2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- End User Insights (Revenue, USD Bn, 2021 - 2033)
- Hospitals and Clinics
- Specialty Endocrine Centers
- Ambulatory Surgical Centers (ASCs)
- Homecare Settings
- Others (Academic and Research Institutes, etc.)
- Regional Insights (Revenue, USD Bn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- Novo Nordisk A/S
- Eli Lilly and Company
- Sanofi
- Pfizer Inc
- Merck & Co Inc
- Novartis AG
- AstraZeneca plc
- AbbVie Inc
- Takeda Pharmaceutical Company Limited
- Bristol-Myers Squibb Company
- Hoffmann-La Roche Ltd
- Ipsen Pharma
- Teva Pharmaceutical Industries Ltd
- Amgen Inc
- Bayer AG
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Endocrinology Drug Market, By Therapy Area
- Global Endocrinology Drug Market, By Route of Administration
- Global Endocrinology Drug Market, By Age Group
- Global Endocrinology Drug Market, By Distribution Channel
- Global Endocrinology Drug Market, By End User
- Global Endocrinology Drug Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Driver
- Restraint
- Opportunity
- Impact Analysis
- Key Developments
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
- Industry Trends
4. Global Endocrinology Drug Market, By Therapy Area, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Diabetes Management Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Insulin (short-acting, long-acting and premixed)
- Oral Antidiabetics (biguanides, sulfonylureas, thiazolidinediones, etc.)
- GLP-1 Receptor Agonists
- Other Combination Therapies
- Thyroid Disorder Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Hypothyroidism Treatments (levothyroxine and liothyronine)
- Hyperthyroidism Treatments (antithyroid drugs and radioiodine therapy adjuncts)
- Growth Hormone Related Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Growth Hormone Deficiency Treatments (recombinant growth hormones, etc.)
- Acromegaly Treatments (somatostatin analogs, GH receptor antagonists, etc.)
- Adrenal Disorder Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Cushing's Syndrome Treatments (steroidogenesis inhibitors, pituitary-targeted drugs)
- Addison's Disease Treatments (glucocorticoids, mineralocorticoids)
- Congenital Adrenal Hyperplasia Drugs
- Reproductive Endocrinology Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Men's Health (testosterone therapies and anti-androgens)
- Women's Health (estrogen therapies, progesterone therapies, etc.)
- Fertility Drugs (gonadotropins, ovulation stimulants, etc.)
- Calcium and Bone Metabolism Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Osteoporosis Treatments (bisphosphonates, SERMs, calcitonin, etc.)
- Hyperparathyroidism Treatments (calcimimetics, vitamin D analogs, etc.)
5. Global Endocrinology Drug Market, By Route of Administration, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Parenteral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Transdermal (patches and gels)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Nasal
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Others (e.g., sublingual and rectal)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
6. Global Endocrinology Drug Market, By Age Group, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Pediatric
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Adult
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Geriatric
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
7. Global Endocrinology Drug Market, By Distribution Channel, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
8. Global Endocrinology Drug Market, By End User, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Hospitals and Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Specialty Endocrine Centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Ambulatory Surgical Centers (ASCs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Homecare Settings
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Others (Academic and Research Institutes, etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
9. Global Endocrinology Drug Market, By Region, 2021 - 2033, Value (USD Bn)
- Introduction
- Market Share (%) Analysis, 2026, 2028 & 2033, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2022 - 2033, Value (USD Bn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Therapy Area, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Therapy Area, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Therapy Area, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Therapy Area, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Therapy Area, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Therapy Area, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country/Region, 2021 - 2033, Value (USD Bn)
- South Africa
- North Africa
- Central Africa
10. Competitive Landscape
- Novo Nordisk A/S
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Eli Lilly and Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sanofi
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Pfizer Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Merck & Co Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Novartis AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- AstraZeneca plc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- AbbVie Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Takeda Pharmaceutical Company Limited
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Bristol-Myers Squibb Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Hoffmann-La Roche Ltd
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Ipsen Pharma
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Teva Pharmaceutical Industries Ltd
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Amgen Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Bayer AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
11. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
12. References and Research Methodology
- References
- Research Methodology
- About Us
